Alzheimer’s anti-tau drug fails phase III, but posts some benefit in monotherapy subanalysis
27/07/2016 - 20:47
TORONTO – A highly anticipated phase III trial of an anti-tau drug has posted negative topline results, conferring no cognitive or functional benefi... More »
